Personalis/$PSNL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Ticker
$PSNL
Sector
Primary listing
Employees
260
Headquarters
Website
Personalis Metrics
BasicAdvanced
$1.3bn
-
-$1.02
2.24
-
Price and volume
Market cap
$1.3bn
Beta
2.24
52-week high
$16.39
52-week low
$3.84
Average daily volume
5m
Financial strength
Current ratio
6.613
Quick ratio
6.307
Long term debt to equity
12.177
Total debt to equity
15.222
Interest coverage (TTM)
-457.69%
Profitability
EBITDA (TTM)
-92.692
Gross margin (TTM)
13.72%
Net profit margin (TTM)
-148.11%
Operating margin (TTM)
-158.91%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-21.41%
Return on equity (TTM)
-41.35%
Valuation
Price to revenue (TTM)
17.782
Price to book
5.05
Price to tangible book (TTM)
5.05
Price to free cash flow (TTM)
-13.553
Free cash flow yield (TTM)
-7.38%
Free cash flow per share (TTM)
-0.906
Growth
Revenue change (TTM)
-24.71%
Earnings per share change (TTM)
-16.72%
3-year revenue growth (CAGR)
-2.06%
3-year earnings per share growth (CAGR)
-25.42%
What the Analysts think about Personalis
Analyst ratings (Buy, Hold, Sell) for Personalis stock.
Personalis Financial Performance
Revenues and expenses
Personalis Earnings Performance
Company profitability
Personalis News
AllArticlesVideos
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL
Business Wire·1 week ago
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Benzinga·1 week ago
PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.